Grants and Contributions:
Title:
Isolation and characterization of neuromodulatory and immunomodulatory mediators from bacteria for application in patients with PANS/PANDAS.
Agreement Number:
956002
Agreement Value:
$661,400.00
Agreement Date:
Jul 1, 2020 - Sep 30, 2022
Description:
Adapsyn’s proprietary drug discovery platform will be applied to the screening of bacteria to discover neuro- and immunomodulatory small molecules to develop therapeutic agents for the treatment of childhood neuropsychiatric disorders.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Hamilton, Ontario, CA L8P 0A1
Reference Number:
172-2020-2021-Q3-956002
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
789183498
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Jul 11, 2022
Recipient's Legal Name:
Adapsyn Bioscience Inc.
Federal Riding Name:
Hamilton Centre
Federal Riding Number:
35035
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: